

CORRECTION

Open Access

# Correction: Guangxi cobra venom-derived NGF promotes the osteogenic and therapeutic effects of porous BCP ceramic

Pan Jin, Fuqiang Yin, Li Huang, Li Zheng, Jinmin Zhao and Xingdong Zhang

**Correction to: *Experimental & Molecular Medicine***  
<https://doi.org/10.1038/emm.2016.173>  
published online 7 April 2017

After online publication of this article, the authors noticed an error in the Figure section. The correct statement of this article should have read as below.

In the article cited above, incorrect figure was placed in Fig. 2C-c. The corrected image of Fig. 2 is printed below. Other parts of this article remain unchanged.


The authors apologize for any inconvenience caused.

Published online: 27 January 2020

© The Author(s) 2020



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.



**Fig. 2 Concentration screening, cytotoxicity assay, FDA-PI staining, rhodamine phalloidin-Hoechst 33258 staining, alkaline phosphatase (ALP) activity assay, ALP staining, osteogenic-specific gene expression and Alizarin red staining of monolayer-cultured osteoblasts. A** Screening of nerve growth factor (NGF) using various concentrations (0.625, 1.25, 2.5, 5, 7.8125, 10, 15.625, 20, 31.25, 62.5, 125, 250 µg ml<sup>-1</sup>) on 2D cultured osteoblasts using the MTT method after 3 days of treatment (n = 3). **B** Cytotoxicity assay with NGF at 0, 2.5, 5 and 10 µg ml<sup>-1</sup> on days 2, 5 and 8 (n = 9). **C** (a–d) FDA-PI staining of osteoblasts treated with NGF at 0, 2.5, 5 and 10 µg ml<sup>-1</sup> after 8 days of treatment (Scale bar = 200 µm). **C** (e–h) Rhodamine phalloidin-Hoechst 33258 staining of a monolayer culture treated with 0, 2.5, 5 and 10 µg ml<sup>-1</sup> NGF after 8 days (Scale bar = 100 µm). **D** ALP activity assay of osteoblasts treated with 0, 2.5, 5 and 10 µg ml<sup>-1</sup> NGF on days 2, 5 and 8 (n = 9). **E** (a–d) ALP staining of osteoblasts treated with 0, 2.5, 5 and 10 µg ml<sup>-1</sup> NGF after 8 days (Scale bar = 500 µm). **F** (a–f) Relative expression of bone morphogenetic protein-2 (*BMP2*, **F** (a)), runt-related transcription factor 2 (*RUNX2*, **F** (b)), alkaline phosphatase (*ALP*, **F** (c)), bone sialoprotein (*BSP*, **F** (d)), osteocalcin (*OCN*, **F** (e)) and alpha-1 type I collagen (*COL1A1*, **F** (f)) in osteoblasts treated with 0, 2.5, 5 and 10 µg ml<sup>-1</sup> NGF on days 2, 5 and 8 (n = 3). **G** (a–d) Alizarin red staining of osteoblasts treated with 0, 2.5, 5 and 10 µg ml<sup>-1</sup> NGF after 8 days (Scale bar = 500 µm). The values are presented as the means ± standard deviation. Bars with different letters at the same time point are significantly different from each other at P < 0.05, and bars with the same letter exhibit no significant difference.